CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)-Reference-Cited by-同舟云学术

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

Published:2013-03 Issue:3 Volume:14 Page:244-248
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pestalozzi Bernhard C,Holmes Eileen,de Azambuja Evandro,Metzger-Filho Otto,Hogge Laurence,Scullion Matt,Láng István,Wardley Andrew,Lichinitser Mikhail,Sanchez Roberto I Lopez,Müller Volkmar,Dodwell David,Gelber Richard D,Piccart-Gebhart Martine J,Cameron David

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial;Gianni;Lancet Oncol,2011

2. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial;Untch;Ann Oncol,2008

3. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet,2007

4. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

5. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”;The Breast;2024-08

2. New treatment options for HER2-positive metastatic breast cancer with leptomeningeal metastases;Meditsinskiy sovet = Medical Council;2024-07-24

3. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis;ESMO Open;2024-05

4. Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?;ESMO Open;2024-05

5. Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis;Breast Cancer Research and Treatment;2024-04-29